|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2004
|
|
gptkbp:ATCCode
|
gptkb:L01XC06
|
|
gptkbp:bindingTarget
|
gptkb:epidermal_growth_factor_receptor
|
|
gptkbp:brand
|
gptkb:Erbitux
|
|
gptkbp:CASNumber
|
gptkb:205923-56-4
|
|
gptkbp:contraindication
|
severe hypersensitivity to cetuximab
|
|
gptkbp:developedBy
|
gptkb:ImClone_Systems
|
|
gptkbp:halfLife
|
112 hours
|
|
gptkbp:immunogenicity
|
can cause allergic reactions
|
|
gptkbp:indication
|
gptkb:squamous_cell_carcinoma_of_the_head_and_neck
metastatic colorectal cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
chimeric monoclonal antibody
|
|
gptkbp:marketedAs
|
gptkb:Eli_Lilly_and_Company
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:mechanismOfAction
|
inhibits EGFR signaling
|
|
gptkbp:notEffectiveAgainst
|
KRAS-mutant tumors
|
|
gptkbp:proteinSequenceOrigin
|
mouse/human chimeric
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
rash
hypomagnesemia
infusion reaction
|
|
gptkbp:target
|
gptkb:EGFR
|
|
gptkbp:UNII
|
PQX0D8J21J
|
|
gptkbp:usedFor
|
colorectal cancer
head and neck cancer
|
|
gptkbp:bfsParent
|
gptkb:EGFR_signaling_pathway
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cetuximab
|